Pemphigus vulgaris: Update on etiopathogenesis, oral manifestations, and management

Critical Reviews in Oral Biology and Medicine

Volumn 13, Issue 5, 2002, Pages 397-408

  Scully, Crispian ^a   Challacombe, Stephen J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmune; Bullous; Corticosteroids; Immunosuppressants; Oral; Pemphigus; Skin; Vesiculobullous

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEFLAZACORT; ETRETINATE; GOLD; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTAGLANDIN E2; AUTOANTIBODY; AUTOANTIGEN; CADHERIN; DESMOGLEIN 1; DESMOGLEIN 3; DSG3 PROTEIN, HUMAN;

AUTOIMMUNITY; BIOPSY; BLISTER; CELLULAR IMMUNITY; DEHYDRATION; DESMOSOME; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOUTH MUCOSA; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; ETHNIC GROUP; GENE; GENETICS; IMMUNOLOGY; MOUTH ULCER; PEMPHIGUS;

ADRENAL CORTEX HORMONES; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; CADHERINS; DESMOGLEIN 1; DESMOGLEIN 3; ETHNIC GROUPS; GENES, MHC CLASS II; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; ORAL ULCER; PEMPHIGUS;

EID: 0036054045     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130201300504     Document Type: Review

References (178)

1. Ahmed AR, Hombal S (1987). Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol 17:437-442.
2. Ahmed AR, Moy R (1982). Death in pemphigus. J Am Acad Dermatol 7:221-228.
3. Ahmed AR, Graham J, Jordon RE, Provost TT (1980). Pemphigus: current concepts. Ann Intern Med 92:396-405.
4. Ahmed AR, Yunis EJ, Khatri K, Wagner R, Notani G, Awdeh Z, et al. (1990). Major histocompatability Author: should be histocompatibility. Please check. complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 87:7658-7662.
5. Ahmed AR, Wagner R, Khatri K, Notani G, Awdeh Z, Alper CA, et al. (1991). Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 88:5056-5060.
6. Ahmed RA, Mohimen A, Yunis EJ, Mirza NM, Kumar V, Beutner EH, et al. (1993). Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 177:419-424.
7. Allen CM, Camisa C (2000). Paraneoplastic pemphigus: a review of the literature. Oral Dis 6:208-214.
8. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR (1992). Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Investig 90:919-926.
9. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T (1995). Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 104:895-901.
10. Ameglio F, D'Auria L, Cordiali-Fei P, Trento E, D'Agosto G, Mastroianni A, et al. (1999). Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients' age. J Biol Regul Homeost Agents 13:220-224.
11. Anhalt GJ, Diaz LA (2001). Prospects for autoimmune disease: research advances in pemphigus. J Am Med Assoc 285:652-654.
12. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. (1990). Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323:1729-1735.
13. Balda BR, Rosenzweig D (1986). Cyclosporin A in the treatment of pemphigus foliaceus and pemphigus erythematosus. Hautarzt 37:454-457.
14. Barnett M (1988). Pemphigus vulgaris presenting as a gingival lesion. A case report. J Periodontol 59:611-614.
15. Barthelemy H, Frappaz A, Cambazard F, Manduit G, Rouchouse B (1988). Treatment of nine cases of pemphigus vulgaris with cyclosporin. J Am Acad Dermatol 18:1262-1266.
16. Basset N, Guillot B, Michel B, Maynadier J, Guihou JJ (1987). Dapsone as initial treatment in superficial pemphigus. Report of 9 cases. Arch Dermatol 123:783-785.
17. Bastuji-Garin S, Turki H, Mokhtar I, Nouira R, Fazaa B, Jomaa B, et al. (2002). Possible relation of Tunisian pemphigus with traditional cosmetics: a multicenter case-control study. Am J Epidemiol 155:249-256.
18. Becker BA, Gaspari AA (1993). Pemphigus vulgaris and vegetans. Dermatol Clin 11:429-453.
19. Bewley AP, Keefe M (1996). Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 135:128-129.
20. Bezold G, Sander CA, Flaig MJ, Peter RU, Messer G (2000). Lack of detection of human herpesvirus (HHV)-8 DNA in lesional skin of German pemphigus vulgaris and pemphigus foliaceus patients. J Invest Dermatol 114:739-741.
21. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR (1995). Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 92:5239-5243.
22. Bialy-Golan A, Brenner S, Anhalt GJ (1996). Paraneoplastic pemphigus: oral involvement as the sole manifestation. Acta Derm Venereol 76:253-254.
23. Blaszczyk M, Chorzelski TP, Daszynski J, Gaczkowski A, Jablouska S, Beutner EH (1981). Plasmapheresis as a supplementary treatment in pemphigus. Arch Immunol Ther Exp 29:763-767.
24. Bredlich RO, Grundmann-Kollmann M, Behrens S, Kerscher M, Peter RU (1999). Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol 141:934.
25. Brenner S, Bialy-Golan A, Ruocco V (1998). Drug-induced pemphigus. Clin Dermatol 16:393-397.
26. Brenner S, Tur E, Shapiro J, Ruocco V, D'Avino M, Ruocco E, et al. (2001). Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 40:562-569.
27. Buxton RS, Magee AI (1992). Structure and interactions of desmosomal and other cadherins. Semin Cell Biol 3:157-167.
28. Bystryn JC (1988). Plasmapheresis therapy of pemphigus. Arch Dermatol 124:1702-1704.
29. Bystryn JC, Steinman NM (1996). The adjuvant therapy of pemphigus; an update. Arch Dermatol 132:203-212.
30. Camisa C, Helm TN, Liu YC, Valenzuela R, Allen C, Bona S, et al. (1992). Paraneoplastic pemphigus: a report of three cases including one long-term survivor. J Am Acad Dermatol 27:547-553.
31. Carcassi C, Cottoni F, Floris L, Vacca A, Mulargia M, Arras M, et al. (1996). HLA haplotypes and class II molecular alleles in Sardinian and Italian patients with pemphigus vulgaris. Tissue Antigens 48:662-667.
32. Carson PJ, Hameed A, Ahmed AR (1996). Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 34:645-652.
33. Checchi L, D'Achille C, Zelent M (1988). Desquamative gingivitis and chlorhexidine. Prev Assist Dent 14:33-40.
34. Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A (1994). Treatment of oral pemphigus vulgaris. Int J Dermatol 33:803-807.
35. Chrysomallis F, Dimitriades A, Chaidemenos GC, Panagiotides D, Karakatsanis G (1995). Steroid-pulse therapy in pemphigus vulgaris long term follow-up. Int J Dermatol 34:438-442.
36. Cohen SS, Weinstein MD, Herndier BG, Anhalt GJ, Blauvelt A (1998). No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. J Invest Dermatol 111:781-783.
37. Cotterill JA, Barker DJ, Millard LG (1978). Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 98:2
38. Cozzani E, Cacciapuoti M, Parodi A, Ghohestani R, Rebora A (2000). Desmosomes and their autoimmune pathologies. Eur J Dermatol 10:255-261.
39. Cunliffe WJ (1987). Pemphigus foliaceus and response to cyclosporin. Br J Dermatol 117(Suppl 32):114-116.
40. Davenport S, Chen SY, Miller AS (2001). Pemphigus vulgaris: clinicopathologic review of 33 cases in the oral cavity. Int J Periodont Rest Dent 21:85-90.
41. Delgado JC, Yunis DE, Bozon MV, Salazar M, Deulofeut R, Turbay D, et al. (1996). MHC class II alleles and haplotypes in patients with pemphigus vulgaris from India. Tissue Antigens 48:668-672.
42. Delgado JC, Hameed A, Yunis JJ, Bhol K, Rojas AI, Rehman SB, et al. (1997). Pemphigus vulgaris autoantibody response is linked to HLA-DQB1*0503 in Pakistani patients. Hum Immunol 57:110-119.
43. Delfino M, Suppa F, Piccirillo A (1986). Pemphigus vulgaris and ulcerative colitis. Dermatologica 172:230.
44. Ding X, Aoki V, Mascaro JM, Lopez-Swiderski A, Diaz LA, Fairley JA (1997). Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 109:592-596.
45. Ding X, Diaz LA, Fairley JA, Giudice GJ, Liu Z (1999). The antidesmoglein 1 auto-antibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol 112:739-743.
46. Dobrev H, Popova L, Vlashev D (1996). Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study. Arch Dermatol Res 288:648-655.
47. Edelson RL (1984). Extra corporeal photopheresis Photodermatology 1:209-210.
48. Eller J, Kest L (1941). Pemphigus: report of seventy-seven cases. Arch Dermatol 44:337-334.
49. Engineer L, Bhol KC, Ahmed AR (2000). Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 43:1049-1057.
50. Enk AH, Knop J (1997). Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 350:494.
51. Enk AH, Knop J (1999). Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 135:54-56.
52. Eversole LR (1994). Immunopathology of oral mucosal ulcerative, desquamative and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral Pathol 77:555-571.
53. Eversole LR, Kenney EB, Sabes WR (1972). Oral lesions as the initial sign in pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 33:354-361.
54. Fabbri P, Emmi L, Vignoli L, Ricci O, Maffia G, Mangia A, et al. (1986). Chronic pemphigus vulgaris associated with ulcerative rectocolitis. Apropos of a clinical case. G Ital Dermatol Venereol 121:355-359.
55. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, et al. (2000). In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-lalpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 114:71-77.
56. Fellner MJ, Katz JM, McCabe JB (1978). Successful use of cyclosphosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol 114:889-894.
57. Femiano F, Gombos F, Scully C (2002). Pemphigus vulgaris with oral involvement; evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 16:353-356.
58. Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ (1992). Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. J Am Med Assoc 267:1500-1502.
59. Gange RW, Rhodes EL, Edwards CO, Powell ME (1976). Pemphigus induced by rifampicin. Br J Dermatol 95:445-448.
60. Gaspar ZS, Walkden V, Wojnarowska F (1996). Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol 37:93-95.
61. Gellis S, Glass F (1941). Pemphigus, a survey of one hundred and seventy patients admitted to Bellevue Hospital from 1911 to 1941. Arch Dermatol 44:321-336.
62. Goldberg I, Kashman Y, Brenner S (1999). The induction of pemphigus by phenol drugs. Int J Dermatol 38:888-892.
63. Goon AT, Tay YK, Tan SH (2001). Pemphigus vulgaris following varicella infection. Clin Exp Dermatol 26:661-663.
64. Grando SA (2000). Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 201:290-295.
65. Gumbiner BM, McCrea PD (1993). Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci Suppl 17:155-158.
66. Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM (2000a). Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 25:236-240.
67. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM (2000b). A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol 143:343-348.
68. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM (2001). The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 144:775-780.
69. Hayag MV, Cohen JA, Kerdel FA (2000). Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 43:1065-1069.
70. Herbst A, Bystryn JC (2000). Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 42:422-427.
71. Hertl M (2000). Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 122:91-100.
72. Hertl M, Riechers R (1999). Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol 26:748-752.
73. Hertl M, Amagai M, Sundaram H, Stanley J, Ishii K, Katz SI (1998a). Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 110:62-66.
74. Hertl M, Karr RW, Amagai M, Katz SI (1998b). Heterogeneous MHC11 restriction pattern of auto-reactive desmoglein 3-specific T cell responses in pemphigus vulgaris patients and normals. J Invest Dermatol 110:388-392.
75. Ioannides D, Chrysomallis F, Bystryn JC (2000). Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 136:868-872.
76. Ishii K, Amagai M, Ohata Y, Shimizu H, Hashimoto T, Ohya K, et al. (2000). Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. J Am Acad Dermatol 42(5 Pt 2):859-861.
77. Jang HS, Oh CK, Lim JY, Jun ES, Kim YS, Kwon KS (2000). Detection of human herpesvirus 8 DNA in pemphigus and chronic blistering skin diseases. J Korean Med Sci 15:442-448.
78. Kalish RS (2000). Pemphigus vulgaris: the other half of the story. J Clin Invest 106:1433-1435.
79. Kanwar AJ, Dhar S (1995). Oral pemphigus vulgaris. Pediat Dermatol 12:195-197.
80. Kaplan RP, Potter TS, Fox JN (1992). Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 26(2 Pt 2):364-366.
81. Korman NJ (2000). New and emerging therapies in the treatment of blistering diseases. Dermatol Clin 18:127-137.
82. Korman NJ, Eyre RW, Zone J, Stanley JR (1991). Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 96:273-276.
83. Kowalewski C, Mackiewicz W, Schmitt D, Jablonska S, Haftek M (2001). Cell-cell junctions in acantholytic diseases. Arch Dermatol Res 293:1-11.
84. Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, Rabinov M, Sulkes J, et al. (2000). The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 143:337-342.
85. Lamey PJ, Rees TD, Binnie WH, Wright JM, Rankin KV, Simpson NB (1992). Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol 74:54-57.
86. Laskaris G, Satriano RA (1993). Drug-induced blistering oral lesions. Clin Dermatol 11:545-550.
87. Laskaris GC, Papavasiliou SS, Bovopoulou OD, Nicolis GD (1980). Association of oral pemphigus with chronic lymphocytic leukemia. Oral Surg Oral Med Oral Pathol 50:244-249.
88. Lever WF, Schaumburg-Lever G (1977). Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961-1975. Arch Dermatol 113:1236-1241.
89. Lever WF, Schaumburg-Lever G (1984). Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 120:44-47.
90. Lin MS, Mascaro JM Jr, Liu Z, Espana A, Diaz LA (1997). The desmosome and hemidesmosome in cutaneous autoimmunity. Clin Exp Immunol 107(Suppl 1):9-15.
91. Loiseau P, Lecleach L, Prost C, Lepage V, Busson M, Bastuji-Garin S, et al. (2000). HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun 15:67-73.
92. Lombardi ML, Mercuro O, Tecame G, Fusco C, Ruocco V, Salerno A, et al. (1996). Molecular analysis of HLA DRB1 and DQB1 in Italian patients with pemphigus vulgaris. Tissue Antigens 47:228-230.
93. Lozada-Nur F, Huang MZ, Zhou G (1991). Open preliminary trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 71:283-287.
94. Lubach D, Reichart P, Wellman W (1984). Oral manifestations during the concurrent appearance of pemphigus and ulcerative colitis. Dtsch Z Mund Kiefer Gesichtschir 8:308-312.
95. Mahé A, Flageul B, Cissé I, Kéita S, Bobin P (1996). Pemphigus in Mali: a study of 30 cases. Br J Dermatol 134:114-119.
96. Markitziu A, Pisanty S (1983). Gingival pemphigus vulgaris. Report of a case. Oral Surg Oral Med Oral Pathol 55:250-252.
97. Mashkilleyson N, Mashkilleyson AL (1988). Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 68:413-421.
98. Matz H, Bialy-Golan A, Brenner S (1997). Diclofenac: a new trigger of pemphigus vulgaris? Dermatology 195:48-49.
99. Matzner Y, Erlich HA, Brautbar C, Sanilevitch A, Landau M, Brenner S, et al. (1995). Identical HLA class II alleles predispose to drug-triggered and idiopathic pemphigus vulgaris. Acta Derm Venereol 75:12-14.
100. Memar OM, Rady PL, Goldblum RM, Yen A, Tyring SK (1997). Human herpesvirus 8 DNA sequences in blistering skin from patients with pemphigus. Arch Dermatol 133:1247-1251.
101. Meurer M, Millns JL, Rogers RS 3rd, Jordon RE (1977). Oral pemphigus. A report of ten cases. Arch Dermatol 113:1520-1524.
102. Mignogna MD, Lo Muzio L, Galloro G, Satriano RA, Ruocco V, Bucci E (1997). Oral pemphigus; clinical significance of esophageal involvement: report of eight cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:179-184.
103. Mignogna MD, Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E (2000). Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. J Oral Pathol Med 29:145-152.
104. Mignogna MD, Pannone G, Lo Muzio L, Staibano S, Bucci E (2001). Catenin dislocation in oral pemphigus vulgaris. J Oral Pathol Med 30:268-274.
105. Miyagawa S, Higashimine I, Iida T, Yamashina Y, Fukumoto T, Shirai T (1997). HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese. J Invest Dermatol 109:615-618.
106. Miyagawa S, Amagai M, Iida T, Yamamoto Y, Nishikawa T, Shirai T (1999). Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: correlation with disease progression. Br J Dermatol 141:1084-1087.
107. Miyagawa S, Niizeki H, Yamashina Y, Kaneshige T (2002). Genotyping for HLA-A, B and C alleles in Japanese patients with pemphigus: prevalence of Asian alleles of the HLA-B15 family. Br J Dermatol 146:52-58.
108. Mobini N, Sarela A, Ahmed AR (1995). Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann Allergy Asthma Immunol 74:119-128.
109. Mobini N, Yunis EJ, Alper CA, Yunis JJ, Delgado JC, Yunis DE, et al. (1997a). Identical MHC markers in non-Jewish Iranian and Ashkenazi Jewish patients with pemphigus vulgaris: possible common Central Asian ancestral origin. Hum Immunol 57:62-67.
110. Mobini N, Padilla T, Ahmed AR (1997b). Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 36:264-266.
111. Morita H, Morisaki S, Kitano Y (1995). Clinical trial of prostaglandin E2 on the oral lesions of pemphigus vulgaris. Br J Dermatol 132:165-166.
112. Mourellou O, Chaidemenos GC, Koussidou T, Kapetis E (1995). The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol 133:83-87.
113. Muller S, Stanley JR (1990). Pemphigus: pemphigus vulgaris and pemphigus foliaceus. In: Management of blistering diseases. Wojnarowska F, Briggaman RA, editors. London: Chapman and Hall Medical, pp. 43-61.
114. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA (2000a). Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Investig 106:1467-1479.
115. Nguyen VT, Ndoye A, Grando SA (2000b). Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 275:29466-29476.
116. Nisengard RJ, Rogers RS 3rd (1987). The treatment of desquamative gingival legions. J Periodontol 58:167-172.
117. Nishifuji K, Amagai M, Kuwana M, Iwasaki T. Nishukawa T (2000). Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 114:88-94.
118. Nishikawa T, Hashimoto T, Shimizu H, Ebihara T, Amagai M (1996). Pemphigus from immunofluorescence to molecular biology. J Dermatol Sci 12:1-9.
119. Ong CS, Cook N, Lee S (2000). Drug-related pemphigus and angiotensin converting enzyme inhibitors. Australas J Dermatol 41:242-246.
120. Orfanos CE, Bauer R (1983). Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br J Dermatol 109(Suppl 25):55-60.
121. Orlowski WA, Bressman E, Doyle JL, Chasens AI (1983). Chronic pemphigus vulgaris of the gingiva. A case report with a 6-year follow-up. J Periodontol 54:685-689.
122. Pasricha JS, Thanzama J, Khan UK (1988). Intermittent highdose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 119:73-77.
123. Pasricha JS, Khaitan BK, Raman RS, Chandra M (1995). Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 34:875-882.
124. Penneys NS, Eaglestein WH, Frost P (1976). Management of pemphigus with gold compounds: a long-term follow-up report. Arch Dermatol 112:185-187.
125. Perniciaro C, Kuechle MK, Colon-Otero G, Raymond MG, Spear KL, Pittelkow MR, et al. (1994). Paraneoplastic pemphigus: a case of prolonged survival. Mayo Clin Proc 69:851-855.
126. Piamphongsant T (1979). Treatment of pemphigus with corticosteroids and cyclosphosphamide. J Dermatol 6:359-363.
127. Pisanty S, Sharav Y, Kaufman E, Posner LN (1974). Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 38:382-387.
128. Prendiville JS, Israel DM, Wood WS, Dimmick JE (1994). Oral pemphigus vulgaris associated with inflammatory bowel disease and herpetic gingivostomatitis in an 11-year old girl. Pediatr Dermatol 11:145-150.
129. Proby CM, Ota T, Suzuki H, Koyasu S, Gamou S, Shimizu N, et al. (2000). Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol 142:321-330.
130. Ramirez-Amador VA, Esquivel-Pedraza L, Orozco-Topete R (2000). Frequency of oral conditions in a dermatology clinic. Int J Dermatol 39:501-505.
131. Robinson JC, Lozada-Nur F, Frieden I (1997). Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:349-355.
132. Roenigk HH Jr, Deodhar S (1973). Pemphigus treatment with azathioprine. Clinical and immunologic correlation. Arch Dermatol 107:353-357.
133. Rosenberg FR, Sanders S, Nelson CT (1976). Pemphigus; a 20 year review of 107 patients treated with corticosteroids. Arch Dermatol 112:962-970.
134. Roujeau JC (1993). Drug-induced toxic epidermal necrolysis. II. Current aspects. Clin Dermatol 11:493-500.
135. Roujeau JC, Kalis B, Lauret P, Flechet ML, Fabre MJ, Andre C, et al. (1982). Plasma exchange in corticosteroid resistant pemphigus. Br J Dermatol 106:103-104.
136. Ruocco V (1988). Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal? Arch Dermatol 124:1716-1718.
137. Ruocco V, Brenner S, Lombardi ML (1996a). A case of diet-related pemphigus. Dermatology 192:373-374.
138. Ruocco V, Wolf R, Ruocco E, Baroni A (1996b). Viruses in pemphigus: a casual or causal relationship? Int J Dermatol 35:782-784.
139. Salomon D, Saurat JH (1986). Oral gold therapy (Auranofin) in pemphigus vulgaris. Dermatologica 172:310-314.
140. Sato M, Aoyama Y, Kitajima Y (2000). Assembly pathway of desmoglein 3 to desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy. Lab Investig 80:1583-1592.
141. Schiltz JR, Michel B (1976). Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 67:254-260.
142. Schwermann M, Lechner W, Elsner C, Kirchner T (1988). Pemphigus vulgaris involving duodenum and colon. Z Hautkr 63:101-104.
143. Sciubba JJ (1996). Autoimmune aspects of pemphigus vulgaris and mucosal pemphigoid. Adv Dent Res 10:52-56.
144. Scully C, Cawson RA (1998). Medical problems in dentistry. 4th ed. Oxford: Butterworth-Heinemann.
145. Scully C, Porter SR (1997). The clinical spectrum of desquamative gingivitis. Semin Cutan Med Surg 16:308-313.
146. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ (1999). Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 140:84-89.
147. Seishima M, Iwasaki-Bessho Y, Itoh Y, Nozawa Y, Amagai M, Kitajima Y (1999). Phosphatidylcholine-specific phospholipase C, but not phospholipase D, is involved in pemphigus IgG-induced signal transduction. Arch Dermatol Res 291:606-613.
148. Shah N, Green AR, Elgart GW, Kerdel F (2000). The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 42(1 Pt 1):85-88.
149. Shah RM, Bilimoria KF (1983). Oral pemphigus vulgaris. Clinico-pathological follow-up of 34 cases. J Oral Med 38:170-173.
150. Shapiro M, Jimenez S, Werth VP (2000). Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol 42(2 Pt 1):297-299.
151. Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K (1998). Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol 110:76-78.
152. Shklar G, Frim S, Flynn E (1978). Gingival lesions of pemphigus. J Periodontol 49:428-435.
153. Sibaud V, Beylot-Barry M, Doutre MS, Beylot C (2000). Successful treatment of corticoid-resistant pemphigus with high-dose intravenous immunoglobulins. Ann Dermatol Venereol 127:408-410.
154. Sinha AA, Brautbar C, Szafer F, Friedmann A, Tzfoni E, Todd JA, et al. (1988). A newly characterized HLA-DQβ allele associated with pemphigus vulgaris. Science 239:1026-1029.
155. Sirois DA, Fatahzadeh M, Roth R, Ettlin D (2000). Diagnostic patterns and delays in pemphigus vulgaris: experience with 99 patients. Arch Dermatol 136:1569-1570.
156. Sklavounou A, Laskaris G (1983). Frequency of desquamative gingivitis in skin diseases. Oral Surg Oral Med Oral Pathol 56:141-144.
157. Stanley JR (2000). Understanding of the pathophysiology of pemphigus suggests innovative therapeutic approaches. Br J Dermatol 142:208-209.
158. Starzycki Z, Chorzelski TP, Jablonska S (1998). Familial pemphigus vulgaris in mother and daughter. Int J Dermatol 37:211-214.
159. Stone DD (1971). Rectal lesions and toxic dilatation of the colon in a case of pemphigus vulgaris. Am J Dig Dis 16:163-166.
160. Swanson DL, Dahl MV (1981). Pemphigus vulgaris and plasma exchange: clinical and serologic studies. J Am Acad Dermatol 4:325-328.
161. Takahashi I, Kobayashi TK, Suzuki H, Nakamura S, Tezuka F (1998). Coexistence of pemphigus vulgaris and herpes simplex virus infection in oral mucosa diagnosed by cytology, immunohistochemistry, and polymerase chain reaction. Diagn Cytopathol 19:446-50.
162. Toto P, Feliciani C, Amerio P, Suzuki H, Wang B, Shivji GM, et al. (2000). Immune modulation in pemphigus vulgaris: role of CD28 and IL-10. J Immunol 164:522-529.
163. Tremeau-Martinage C, Oksman F, Bazex J (1995). Immunoglobulin G subclass distribution of anti-intercellular substance antibodies in pemphigus. Ann Dermatol Venereol 122:409-411.
164. Tsunoda K, Ota T, Suzuki H, Ohyama M, Nagai T, Nishikawa T, et al. (2002). Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol 32:627-633.
165. Tufano MA, Baroni A, Buommino E, Ruocco E, Lombardi ML, Ruocco V (1999). Detection of herpesvirus DNA in peripheral blood mononuclear cells and skin lesions of patients with pemphigus by polymerase chain reaction. Br J Dermatol 141:1033-1039.
166. Tur E, Brenner S (1998). Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Arch Dermatol 134:1406-1410.
167. Turner MS, Sutton D, Sauder DN (2000). The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 43:1058-1064.
168. Uitto J, Pulkkinen L (1996). Molecular complexity of the cutaneous basement membrane zone. Mol Biol Rep 23:35-46.
169. Virgili A, Thrombelli L, Calura G (1992). Sudden vegetation of the mouth. Pemphigus vegetans of the mouth (Hallopeau type). Arch Dermatol 128:398-399, 401-402.
170. Weinberg MA, Abitbol TE (1995). Pemphigus vulgaris; gingival involvement. Ann Dent 54:8-13.
171. Weinberg MA, Insler MS, Campen RB (1997). Mucocutaneous features of autoimmune blistering diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:517-534.
172. Werth VP (1996). Treatment of pemphigus vulgaris with brief high-dose intravenous glucocorticoids. Arch Dermatol 132:1435-1439.
173. Wolf R, Brenner S (1994). An active amide group in the molecule of drugs that induce pemphigus: a casual or causal relationship? Dermatology 189:1-4.
174. Wolf R, Tamir A, Brenner S (1991). Drug-induced versus drug-triggered pemphigus. Dermatologica 182:207-210.
175. Wong KC, Ho KK (2000). Pemphigus with pemphigoid-like presentation, associated with squamous cell carcinoma of the tongue. Australas J Dermatol 41:178-180.
176. Wu SJ, Tanphaichitr A, Ly M (2002). Recent advances in dermatology. Clin Podiatr Med Surg 19:65-78.
177. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, et al. (1995). Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 92:11935-11939.
178. Zegarelli D, Zegarelli E (1977). Intraoral pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 44:384-393.